Serum HER-2/neu as a Prediction and Monitoring Parameter in a Phase II Study with Weekly Paclitaxel in Metastatic Breast Cancer

Anticancer Research

Volumn 24, Issue 2 B, 2004, Pages 895-906

  Lüftner, Diana ^a   Henschke, Petra ^a   Flath, Bernd ^a   Akrivakis, Costa ^a   Schnabel, Sonja ^a   Prinz, Berit ^a   Geppert, Rita ^a   Wernecke, Klaus Dieter ^a   Possinger, Kurt ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Fractionated paclitaxel; Metastatic breast cancer; Monitoring; Predictive markers; Serum HER 2 neu

Indexed keywords

ONCOPROTEIN; PACLITAXEL;

ADULT; ARTICLE; BLOOD LEVEL; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; METASTASIS; ONCOGENE NEU; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SERUM;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASM METASTASIS; PACLITAXEL; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 2442598228     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Bargmann CI, Hung MC and Weinberg RA: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319(6050): 226-230, 1986.
2. Padhy LC, Shih C, Cowing D, Finkelstein R and Weinberg RA: Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell 28(4): 865-871, 1982.
3. Brandt-Rauf PW, Pincus MR and Carney WP: The c-erbB-2 protein in oncogenesis: molecular structure to molecular epidemiology. Crit Rev Oncog 5(2-3): 313-329, 1994.
4. Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J and Baselga J: Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 59(6): 1196-1201, 1999.
5. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785): 177-182, 1987.
6. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905): 707-712, 1989.
7. Andersen TI, Paus E, Nesland JM, McKenzie SJ and Borresen AL: Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour. Acta Oncol 34(4): 499-504, 1995.
8. Krainer M, Brodowicz T, Zeillinger R, Wiltschke C, Scholten C, Seifert M et al: Tissue expression and serum levels of HER-2/neu in patients with breast cancer. Oncology 54(6): 475-481, 1997.
9. Baselga J, Seidman AD, Rosen PP and Norton L: HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology (Huntingt) 11(3 Suppl 2): 43-48, 1997.
10. Yamauchi H, Stearns V and Hayes DF: When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 19(8): 2334-2356, 2001.
11. Harris LN, Liotcheva V, Broadwater G, Ramirez MJ, Maimonis P, Anderson S et al: Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol 19(6): 1698-1706, 2001.
12. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47(1): 207-214, 1981.
13. Cook GB, Neaman IE, Goldblatt JL, Cambetas DR, Hussain M, Luftner D et al: Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer. Anticancer Res 21(2B): 1465-1470, 2001.
14. Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, Clark GM et al: HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 4(1): 7-12, 1998.
15. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A et al: c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14(10): 2702-2708, 1996.
16. Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H et al: Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13(5): 1129-1135, 1995.
17. Molina R, Jo J, Filella X, Zanon G, Pahisa J, Mu nM et al: c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat 51(2): 109-119, 1998.
18. Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A et al: Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 6(6): 2356-2362, 2000.
19. Stender MJ, Neuberg D, Wood W and Sledge G: Correlation of circulating c-erb B-2 extracellular domain (Her-2) with clinical outcome in patients with metastatic breast cancer (MBC). Proc Ann Meet Am Soc Clin Oncol 16: A541, 1997.
20. Volm M, Yee H, Symmans WF, Formenti S, Oratz R, Shapiro R et al: HER2 status predicts response to preoperative paclitaxel in patients with breast cancer. Proc Ann Meet Am Soc Clin Oncol 18: A394, 1999.
21. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ and Slamon DJ: The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15(5): 537-547, 1997.
22. Konecny G, Thomssen C, Pegram M, Lück H, Untch M, Pauletti G et al: HER-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol 20: 23a, 2001.
23. Braun S, Schlimok G, Heumos I, Schaller G, Riethdorf L, Riethmuller G et al: ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res 61(5): 1890-1895, 2001.
24. Chariyalertsak S, Sugano K, Ohkura H and Mori Y: Comparison of c-erbB-2 oncoprotein expression in tissue and serum of patients with stomach cancer. Tumour Biol 15(5): 294-303, 1994.
25. Jimenez RE, Grignon DJ, Vaishampayan U and Hussain M: Analysis of HER-2/neu overexpression in primary and metastatic transitional cell carcinoma of the bladder. Proc Ann Meet Am Soc Clin Oncol 19: 329a, 2000.
26. Roetger A, Merschjann A, Dittmiar T, Jackisch C, Barnekow A and Brandt B: Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by use of an extravasation model. Am J Pathol 153(6): 1797-1806, 1998.
27. Brandt B, Roetger A, Heidl S, Jackisch C, Lelle RJ, Assmann G et al: Isolation of blood-borne epithelium-derived c-erbB-2 oncoprotein-positive clustered cells from the peripheral blood of breast cancer patients. Int J Cancer 76(6): 824-828, 1998.
28. Edgerton SM, Merkel DE, Moore DH and Thor AD: HER-2/neu/ErbB-2 status by immunohistochemistry and FISH: Clonality and progression with recurrence and metastases. Breast Cancer Res Treat 64(1): 55, 2000.
29. Cardoso F, Di Leo A, Larsimont D, Gancberg D, Rouas G, Dolci S et al: Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol 12(5): 615-620, 2001.
30. Pegram MD, Lipton. A, Hayes DF, Weber BL, Baselga JM, Tripathy D et al: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16(8): 2659-2671, 1998.
31. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J and Baselga J: Trastuzumab (herceptin), a humanized anti-her2 receptor monoclonal antibody, inhibits basal and activated her2 ectodomain cleavage in breast cancer cells. Cancer Res 61(12): 4744-4749, 2001.
32. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17(9): 2639-2648, 1999.
33. Seidman AD, Hudis CA, Albanel J, Tong W, Tepler I, Currie V et al: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16(10): 3353-3361, 1998.
34. Perez EA, Irwin DH, Patel R, Vogel CL and Kirshner J: A large phase II trial of paclitaxel administered as a weekly one hour infusion in patients with metastatic breast cancer. Proc Ann Meet Am Soc Clin Oncol 18: 126a, 1999.
35. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A et al: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19(10): 2587-2595, 2001.
36. Sporn JR and Bilgrami SA: Weekly paclitaxel plus Herceptin in metastatic breast cancer patients who relapse after stem-cell transplant. Ann Oncol 10(10): 1259-1260, 1999.
37. Kohler U, Olbricht SS, Fuechsel G, Kettner E, Richter B and Ridwelski K: Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer: results of a clinical phase II study. Semin Oncol 24(5 Suppl 17): S17-S17, 1997.
38. Baselga J, Norton L, Albanell J, Kim YM and Mendelsohn J: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58(13): 2825-2831, 1998.